NO964465D0 - Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling - Google Patents

Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling

Info

Publication number
NO964465D0
NO964465D0 NO964465A NO964465A NO964465D0 NO 964465 D0 NO964465 D0 NO 964465D0 NO 964465 A NO964465 A NO 964465A NO 964465 A NO964465 A NO 964465A NO 964465 D0 NO964465 D0 NO 964465D0
Authority
NO
Norway
Prior art keywords
heparin
binding protein
hbp
treatment
protein
Prior art date
Application number
NO964465A
Other languages
English (en)
Norwegian (no)
Other versions
NO964465L (no
Inventor
Hans Jakob Hem Flodgaard
Poul Baad Rasmussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO964465L publication Critical patent/NO964465L/no
Publication of NO964465D0 publication Critical patent/NO964465D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO964465A 1994-04-21 1996-10-21 Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling NO964465D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK46494 1994-04-21
DK145294 1994-12-21
PCT/DK1995/000121 WO1995028949A1 (en) 1994-04-21 1995-03-17 Heparin-binding protein for the treatment of sepsis and processes for its preparation

Publications (2)

Publication Number Publication Date
NO964465L NO964465L (no) 1996-10-21
NO964465D0 true NO964465D0 (no) 1996-10-21

Family

ID=26064054

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964465A NO964465D0 (no) 1994-04-21 1996-10-21 Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling

Country Status (15)

Country Link
EP (1) EP0762889B1 (ru)
JP (1) JPH09512168A (ru)
CN (1) CN1146724A (ru)
AT (1) ATE239494T1 (ru)
AU (1) AU703963B2 (ru)
CA (1) CA2188395A1 (ru)
CZ (1) CZ289439B6 (ru)
DE (1) DE69530689T2 (ru)
FI (1) FI964227A (ru)
HU (1) HU221638B1 (ru)
NO (1) NO964465D0 (ru)
NZ (2) NZ332683A (ru)
PL (1) PL316935A1 (ru)
RU (1) RU2200573C2 (ru)
WO (1) WO1995028949A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607916A (en) * 1989-07-05 1997-03-04 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
AU8012398A (en) * 1997-06-25 1999-01-19 Novo Nordisk A/S Use of heparin-binding protein for inhibiting entry of pathogens into mononuclear cells
WO1999000417A1 (en) * 1997-06-25 1999-01-07 Novo Nordisk A/S Production of heparin-binding protein in mammalian cells
WO2000066627A1 (en) * 1999-04-29 2000-11-09 Leukotech A/S Expression of heparin-binding protein in recombinant mammalian cells
GB0521276D0 (en) * 2005-10-19 2005-11-30 Lewitt Moira S Medical uses and therapies based upon the action of azurocidin on IGFBP-1
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
CN110903375A (zh) * 2019-10-12 2020-03-24 南京立顶生物科技有限公司 一种肝素结合蛋白生产提纯方法
CN110726846B (zh) * 2019-12-04 2022-08-26 南京市儿童医院 Hbp蛋白作为川崎病的诊断标志物的应用
CN113945718A (zh) * 2020-03-04 2022-01-18 上海奥普生物医药股份有限公司 一种肝素结合蛋白检测试剂盒、制备方法及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228370A (en) * 1988-03-17 1994-01-26 Novo Nordisk As Heparin-binding protein and preparation thereof.
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
GB9017008D0 (en) * 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor

Also Published As

Publication number Publication date
DE69530689T2 (de) 2004-03-25
NZ332683A (en) 2001-06-29
CZ289439B6 (cs) 2002-01-16
CZ308296A3 (en) 1997-08-13
RU2200573C2 (ru) 2003-03-20
WO1995028949A1 (en) 1995-11-02
HU221638B1 (hu) 2002-12-28
NZ284434A (en) 1998-12-23
CN1146724A (zh) 1997-04-02
NO964465L (no) 1996-10-21
FI964227A0 (fi) 1996-10-21
FI964227A (fi) 1996-10-21
HUT75557A (en) 1997-05-28
JPH09512168A (ja) 1997-12-09
HU9602895D0 (en) 1996-12-30
PL316935A1 (en) 1997-02-17
AU703963B2 (en) 1999-04-01
ATE239494T1 (de) 2003-05-15
CA2188395A1 (en) 1995-11-02
DE69530689D1 (de) 2003-06-12
AU2303395A (en) 1995-11-16
EP0762889A1 (en) 1997-03-19
EP0762889B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
Habicht et al. Lyme disease spirochetes induce human and murine interleukin 1 production.
Liang et al. Binding of heparan sulfate to Staphylococcus aureus
FR2646437B1 (fr) Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
NO964465L (no) Heparinbindende protein for behandling av sepsis, og fremgangsmåter for dets fremtilling
IL207348A0 (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them, and use thereof in the manufacture of medicinal products for producing recombinant proteins in vivo
DE69737125D1 (de) Streptococcus pneumoniae antigene und impfstoffe
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
ES2215324T3 (es) Mcp-2 amino-terminalmente truncadas como antagonistas de la quimioquina.
DE69233143D1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
Van Damme et al. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8
MA22139A1 (fr) Procede co-hydrolytique pour la production de nouveaux extraits de proteines de la levure et de produits n'en contenant pas
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin
NO983238L (no) Exodus kjemokin materialer og fremgangsmÕter
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
RU96122777A (ru) Связывающий гепарин белок для лечения сепсиса и способы его получения
MX9604953A (es) Proteina que une heparina, para el tratamiento de sepsis y procesos para su preparacion.
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
JP2969461B2 (ja) ヒトγ−インターフェロンとその製造方法並びに用途
Yasuda et al. Partial purification and characterization of feline gamma-like interferon
Takeda et al. The production of a cytotoxic factor by mouse peritoneal macrophages and macrophage hybridomas treated with various stimulating agents
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
EP0603393A4 (en) INTERLEUKIN 6 HUMAN RECOMBINATION WITH HOMOGENEOUS N TERMINATION AND PRODUCTION OF THIS INTERLEUKIN.
TH17361A (th) โปรตีนจากรีคอมบิแนนท์ มิวแทนท์ ของpasteurella multocida กรรมวิธีสำหรับเตรียมลำดับดีเอนเอที่มีประมวลรหัสของโปรตีนเรพลิคอนที่มีลำดับดีเอนเอและเซลล์ที่ทรานสฟอร์มด้วยเรพลิคอนดังกล่าวชนิดเดียวกัน
WO1992006112A1 (en) Activated ctap and analogs thereof and their use
DE69126379D1 (de) Verfahren zur herstellung und reinigung des carboxyterminalen fragments der dna-polymerase i von streptococcus pneumoniae

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application